Themenkomplex III: Therapie der nichterosiven Refluxkankheit (NERD)

H. Koop; M. Classen; S. Liebe; A. Lütke; M. Wienbeck

doi:10.1055/s-2005-857873

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2005; 43(2): 176-179
DOI: 10.1055/s-2005-857873

Leitlinie

Themenkomplex III: Therapie der nichterosiven Refluxkankheit (NERD)

H. Koop, M. Classen, S. Liebe, A. Lütke, M. Wienbeck

Abstract

Full Text

References

Literatur

1 Fang J, Bjorkman D. A critical approach to noncardiac chest pain: pathophysiology, diagnosis and treatment. Am J Gastroenterol. 2001; 96 958-968
2 Achem S R, Kolts B E, MacMath T. et al . Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sc. 1997; 42 2138-2145
3 Watson R GP, Tham T CK, Johnston B T. et al . Double-blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the „sensitive oesophagus”. Gut. 1997; 40 587-590
4 Carlsson R, Dent J, Bolling-Sternevald E. et al . The usefulness of structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998; 33 1023-1029
5 Venables T L, Newland R D, Patel A C. et al . Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general pratice. Scand J Gastroenterol. 1997; 32 965-973
6 Venables T L, Newland R D, Patel A C. et al . Maintenance treatment for gastro-oesophageal reflux. Scand J Gastroenterol. 1997; 32 627-632
7 Lind T, Havelund T, Lundell L. et al . On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomised trial. Aliment Pharmacol Ther. 1999; 13 907-914
8 Talley N J, Lauritsen K, Tunturi-Hahnala H. et al . Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther. 2001; 15 347-354
9 Martinez S D, Malagon I B, Garewal H S. et al . Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003; 17 537-545
10 Lind T, Havelund T, Carlsson R. et al . Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997; 32 974-979
11 Lauritsen K. Management of endoscopy-negative reflux disease: progress with short-term treatment. Aliment Pharmacol Ther. 1997; 11 (Suppl 2) 87-92
12 Lundell L. New information relevant to long-term management of endoscopy-negative reflux disease. Aliment Pharmacol. 1997; 11 (Suppl 1) 93-98
13 Havelund T, Lind T, Wiklund I. et al . Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol. 1999; 94 1782-1789
14 Wiklund I, Bardhan K D, Muller-Lissner S. et al . Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trialzzzThe European Study Group. Ital J Gastroenterol. 1998; 30 19-27
15 Carlsson R, Dent J, Watts R. et al . Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. nternational GORD Study Group. Eur J Gastroenterol Hepatol. 1998; 10 119-124
16 Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2000; 95 2692-2697
17 Bate C M, Griffin S M, Keeling P WN. et al . Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther. 1996; 10 547-555
18 Graham D Y, Smith J L, Patterson D J. Why do apparently healthy people use antacid tablets?. Am J Gastroenterol. 1983; 78 257-260
19 Simon B, Raveli G P, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1996; 10 441-446
20 Reynolds J C. Individualized acute treatment strategies for gastrooesophageal reflux disease. Scand J Gastroenterol. 1995; Suppl 213 17-24
21 Hatlebakk J G, Hyggen A, Madsen P H. et al . Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Brit med J. 1999; 319 550-553
22 Galmiche J P, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Therap. 1997; 11 765-773
23 Pinxteren, Numans M E, Bonis P A. et al . Short-term treatment with proton pump inhibitors, H2 receptor antagonists, and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrance Database Syst Rev. 2000; 2 CD002095
24 Sabesin S M, Berln R G, Humphries T J. et al . Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results from a multicenter, placebo-controlled, dose-ranging study. Arch Intern Med. 1991; 151 2394-2400
25 Richter J E, Kovacs T O, Greski-Rose P A. et al . Lansoprazole in the treatment of heartburn in patient without erosive oesophagitis. Aliment Pharmacol Ther. 1999; 13 795-804
26 Richter J E, Peura D, Benjamin S B. et al . Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000; 160 1810-1816
27 Bytzer P, Blum A, de Herdt D. et al . Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004; 20 181-188
28 Armstrong D, Paré P, Pericak D. et al . Symptom relief in gastroesophageal relux disease: a radomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001; 96 2849-2857
29 van Pinxteren B, Numans M E, Lau J. et al . Short-term treatment of gastroesophageal reflux disease. J Gen Inern Med. 2003; 18 755-763
30 Kharilas P J, Fennerty M B, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol. 1999; 94 92-97
31 Armstrong D, Talley N J, Lauritsen K. et al . The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004; 20 413-421
32 Howden C W, Henning J M, Huang B. et al . Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol. 2001; 96 1704-1710
33 Bardhan K D, Müller-Lissner S, Bigard M A. et al . Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole and ranitidine. Brit med J. 1999; 318 502-507
34 Filipi C J, Lehman G A, Rothstein R I. et al . Transoral flexible endoscopic sturing for treament of GERD: a multicenter trial. Gastrointest Endosc. 2001; 53 416-422
35 Chuttani R, Sud R, Sachdev G. et al . A novel endoscopic full-thickness plicator for the treatment of GERD: a pilot study. Gastrointest Endosc. 2003; 58 770-776
36 Triadafilopouslos G, DiBaise J K, Nostrant T T. et al . The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. Gastrointest Endosc. 2002; 55 149-156
37 Johnson D A, Ganz R, Aisenberg J. et al . Endoscopic implantation of enteryx for treatment of GERD: 12-month results of a prospective, multicenter trial. Am J Gastroenterol. 2003; 98 1909-1912
38 Kahrilas P J. Radiofrequency energy tretment of GERD. Gastroenterology. 2003; 125 970-973
39 Corley D A, Katz P, Wo J M. et al . Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology. 2003; 125 668-676